Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 12;11(11):1779. doi: 10.3390/cancers11111779

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Hematological cells response to S63845, trametinib, and combination treatment. Cell viability assessments in mononuclear cells of AML (A), other hematological malignancies (B), and normal cells treated for 20 h with S63845 and trametinib alone or in combination. All values are in reference to mock treated cells (= 100% viability). Statistical significance is indicated for the effects of single versus combination treatments. (C) Clinical characteristics of the AML and other hematological malignancies. Acute myeloid leukemia (AML), acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), chronic myeloid leukemia (CML), B-cell lymphoma (BCL), mantle cell lymphoma (MCL). Peripheral blood (PB), bone marrow (BM), normal karyotype (NK), complex karyotype (CK). Relapsed/refractory (R/R). Susceptibility of grouped AML subsets to trametinib (D), S638 (E), and combination treatment (F). Significance is denoted for p < 0.05 (*); p < 0.005 (**); p < 0.0005 (***); p > 0.05 (ns).